Trial Profile
Efficacy of mycobactovir (Myc-102) in patients with acute exacerbation of chronic vulvovaginal candidiasis: A multicenter, randomised, double-blind phase III study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2018
Price :
$35
*
At a glance
- Drugs Myc 102 (Primary)
- Indications Vulvovaginal candidiasis
- Focus Therapeutic Use
- 21 Jul 2018 New trial record
- 11 Jun 2018 Primary endpoint of mycological response rate at 7 day has been met, according to results presented the ASM microbe 2018.
- 11 Jun 2018 Results presented at the ASM Microbe 2018